Food and Drug Administration
Joint meeting of the
Transmissible Spongiform Encephalopathies Advisory
Committee
and the
Blood Products Advisory Committee
January 17, 2002
Slides
FDA Final Guidance "Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products," Dorothy Scott, MD, FDA ppt htm
Effectiveness of measures taken to protect humans from food-borne exposure to the BSE agent: Implications for risk of variant Creutzfeldt-Jakob disease and blood safety, David M Asher, MD, CBER, FDA ppt htm
Variant CJD, An Update, Dr Hester Ward, National CJD Surveillance Centre, UK ppt htm
Food chain Protection in the UK, Peter Soul, Department for Environment, Food and Rural Affairs ppt htm
Efforts and needs for global control of BSE and vCJD, Marua N Ricketts MD, MHSc, FRCPC, WHO, CDS, CSR, EPH ppt htm
Evaluation of the Potential for BSE in the United States, George M Gray PhD and Joshua Cohen PhD, Harvard School of Public Health, Boston ppt htm
Open Public Hearing (Posted 04/04/02)
Statement from the New York Blood Center pdf
America's Blood Centers, Celso Bianco, MD pdf
National Hemophilia Foundation pdf
Alpha-1 Foundation, Miriam O'Day pdf